Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Clin Cancer Res
; 19(10): 2677-87, 2013 May 15.
Article
em En
| MEDLINE
| ID: mdl-23532886
ABSTRACT
PURPOSE:
To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug. EXPERIMENTALDESIGN:
Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. The apoptotic effect over multiple myeloma patient samples was studied ex vivo by cytometry. The mechanism of action of TG02 was analyzed in the cell line MM1S, studying its effect on the cell cycle, the induction of apoptosis, and the loss of mitochondrial membrane potential by cytometry and Western blot. Two models of multiple myeloma xenograft were utilized to study the in vivo action of TG02.RESULTS:
TG02 potently inhibited proliferation and survival of multiple myeloma cell lines, even under protective bone marrow niche conditions, and selectively induced apoptosis of primary patient-derived malignant plasma cells. TG02 displayed significant single-agent activity in two multiple myeloma xenograft models, and enhanced the in vivo activity of bortezomib and lenalidomide. Signaling analyses revealed that the drug simultaneously blocked the activity of CDKs 1, 2, and 9 as well as the MAP kinase ERK5 in MM1S cells, leading to cell-cycle arrest and rapid commitment to apoptosis. TG02 induced robust activation of both the intrinsic and extrinsic pathways of apoptosis, and depletion of XIAP and the key multiple myeloma survival protein Mcl-1.CONCLUSIONS:
TG02 is a promising new antimyeloma agent that is currently in phase I clinical trials in leukemia and multiple myeloma patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinases Ciclina-Dependentes
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Proteína Quinase 7 Ativada por Mitógeno
/
Compostos Heterocíclicos de 4 ou mais Anéis
/
Mieloma Múltiplo
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article